| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2024
(7 months from now) | |
| US7612114 | STEMLINE THERAP | Selective estrogen receptor modulator |
Aug, 2026
(2 years from now) | |
| US10385008 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCL |
Jan, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11779552 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(10 years from now) | |
| US10420734 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(10 years from now) | |
| US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(10 years from now) | |
| US11819480 | STEMLINE THERAP | Methods for treating cancer |
Nov, 2036
(12 years from now) | |
| US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(13 years from now) | |
Orserdu is owned by Stemline Therap.
Orserdu contains Elacestrant Dihydrochloride.
Orserdu has a total of 8 drug patents out of which 0 drug patents have expired.
Orserdu was authorised for market use on 27 January, 2023.
Orserdu is available in tablet;oral dosage forms.
Orserdu can be used as treatment of an er-positive breast cancer following at least one line of endocrine therapy, treatment of an er-positive breast cancer.
Drug patent challenges can be filed against Orserdu from 27 January, 2027.
The generics of Orserdu are possible to be released after 05 January, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer
Dosage: TABLET;ORAL
ORSERDU family patents
